[关键词]
[摘要]
目的 探讨天蟾胶囊联合盐酸羟考酮缓释片治疗中度癌痛的临床疗效。方法 选取2015年6月-2017年12月在郑州市第六人民医院呼吸内科由于各种类型的癌症出现中度疼痛的167例住院患者,入组患者按照随机表法随机分为对照组(83例)和治疗组(84例)。对照组口服盐酸羟考酮缓释片,按患者疼痛程度调整每次服用量,2次/d。治疗组在对照组治疗的基础上口服天蟾胶囊,1粒/次,3次/d。患者在服药前用VSA评分评价其疼痛强度,作为基线的疼痛强度,给药5 d后评价其疼痛强度。比较两组患者止痛起效时间、盐酸羟考酮日均服用量、疼痛强度、生活质量改善情况和镇痛效果。结果 治疗组止痛起效时间明显短于对照组,两组比较差异具有统计学意义(P<0.05)。治疗第2天时,治疗组患者服用羟考酮的量比对照组略少,但二者不存在统计学差异。治疗第5天时,治疗组患者服用羟考酮少于对照组,二者存在统计学差异(P<0.05)。治疗后,两组患者VAS评分均有明显下降(P<0.05)。治疗后,治疗组患者的VAS评分与对照组相比更低,差异具有统计学意义(P<0.05)。治疗组、对照组KPS评分增加大于10分例数比较差异具有统计学意义(P<0.05)。对照组、治疗组的疼痛缓解率分别为79.52%、94.05%,治疗组疼痛缓解率与对照组相比,差异具有统计学意义(P<0.05)。对照组、治疗组的不良事件发生率分别为21.7%、20.2%,治疗组和对照组相比,不良反应差异没有统计学意义。结论 天蟾胶囊联合盐酸羟考酮缓释片治疗中度癌痛具有良好的临床效果,可以改善患者生活质量,降低疼痛强度,同时安全性良好。
[Key word]
[Abstract]
Objective To investigate the clinical effect of Tianchan Capsules combined with Oxycodone Hydrochloride Prolonged-release Tablets in treatment of moderate cancer pain. Methods Patients (167 cases) with moderate cancer pain in Department of Respiratory Medicine of Zhengzhou Sixth People's Hospital from June 2015 to December 2017 were randomly divided into control group (83 cases) and treatment group (84 cases) according to random table method. Patients in the control group were po administered with Oxycodone Hydrochloride Prolonged-release Tablets, the dosage adjusted according to the degree of pain, twice daily. Patients in the treatment group were po administered with Tianchan Capsules on the basis of the control group, 1 grain/time, three times daily. The pain intensity was evaluated by VSA score before medication as the baseline pain intensity. The pain intensity was evaluated 5 d after administration. The onset time of pain relief, daily dosage of oxycodone hydrochloride, pain intensity, improvement of quality of life and analgesic effect were compared between the two groups. Results The onset time of pain relief in the treatment group was significantly shorter than that in the control group with statistical significance (P<0.05). On the second day of treatment, the amount of oxycodone in the treatment group was slightly less than that in the control group, but there was no statistical difference between the two groups. On the 5th day of treatment, the dosage of patients in the treatment group was less than that in the control group with statistical significance (P<0.05). After treatment, the VAS score of two groups were significantly decreased (P<0.05), and the VAS score of the treatment group were significantly lower than those of the control group (P<0.05). Patients of KPS score increased more than 10 points in the treatment group were higher than those in the control group, and the difference was statistically significant (P<0.05). The pain relief rates of the control group and the treatment group were 79.52% and 94.05%, respectively, and there was statistically significant between two groups (P<0.05). The incidences of adverse reaction in two groups were 21.7% and 20.2%, respectively, but there was no significant difference in the incidence of adverse reactions between two groups. Conclusion Tianchan Capsules combined with Oxycodone Hydrochloride Prolonged-release Tablets has good clinical effect in treatment of moderate cancer pain, can improve the quality of life of patients, reduce the intensity of pain, and has good safety.
[中图分类号]
R978
[基金项目]
郑州市科技计划项目(141PPTGG315)